We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Passage Bio Inc (PASG) USD0.0001

Sell:$2.16 Buy:$2.18 Change: $0.06 (2.70%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$2.16
Buy:$2.18
Change: $0.06 (2.70%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
Sell:$2.16
Buy:$2.18
Change: $0.06 (2.70%)
Market closed |  Prices as at close on 8 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Passage Bio, Inc. is a clinical stage genetic medicines company. The Company is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (ß-gal), for GM1. Its second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), for FTD caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosyl ceramidase, (GALC) for Krabbe disease. The Company also has six programs in the research stage: PBML04 for metachromatic leukodystrophy; PBAL05 for amyotrophic lateral sclerosis; PBCM06 for Charcot-Marie-Tooth Type 2A; and programs for Canavan disease, and others.

Contact details

Address:
One Commerce Square
2005 Market Street, 39Th Floor
PHILADELPHIA
19103
United States
Telephone:
+1 (267) 8660312
Website:
https://www.passagebio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PASG
ISIN:
US7027121000
Market cap:
$120.56 million
Shares in issue:
54.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Maxine Gowen
    Interim Executive Chairwoman of the Board
  • Edgar Cale
    Interim Chief Executive Officer
  • Simona King
    Chief Financial Officer
  • Alexandros Fotopoulos
    Chief Technical Officer
  • Mark Forman
    Chief Medical Officer
  • Maria Toernsen
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.